Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Featured trial
A Clinical Study of Intravenous Administration of RT-01 in Patients With Advanced Solid Tumors

This is an open-label, dose escalation study of the safety and tolerability of oncolytic virus injection(RT-01) when administered via Intravenous injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of RT-01 and to determine the recommended phase 2 dose (RP2D) …

  • 0 views
  • 14 Mar, 2022
  • 1 location
Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

The purpose of this study is to assess the efficacy and safety of intratumoral (IT) MK-1454 in PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

pembrolizumab
systemic therapy
squamous cell carcinoma of head and neck
carcinoma
HIV Infection
  • 0 views
  • 16 Feb, 2024
  • 18 locations
Enfortumab Vedotin and Pembrolizumab With or Without Chemotherapy vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together alone or with platinum chemotherapy to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care).

adjuvant
external beam radiation therapy
metastatic urothelial carcinoma
immunomodulator
pembrolizumab
  • 0 views
  • 16 Feb, 2024
  • 26 locations
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

pembrolizumab
antihypertensive agents
hcv infection
carcinoma
hepatitis b
  • 0 views
  • 16 Feb, 2024
  • 38 locations
GNOS-PV02 Personalized Neoantigen Vaccine INO-9012 and Pembrolizumab in Subjects With Advanced HCC

This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.

chronic infection
pembrolizumab
sorafenib
liver cancer
antiviral therapy
  • 0 views
  • 16 Feb, 2024
  • 3 locations
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Antibodies

solid tumor
growth factor
pembrolizumab
non-small cell lung cancer
lung cancer
  • 0 views
  • 16 Feb, 2024
  • 8 locations
TAK-676 as Single Agent (SA) and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of TAK-676 administered as an SA or in combination with pembrolizumab in participants with advanced or metastatic solid tumors.

pembrolizumab
hair thinning
neuropathy
solid tumour
programmed cell death protein 1
  • 0 views
  • 05 Aug, 2020
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.

head and neck cancer
pembrolizumab
monoclonal antibodies
monoclonal antibody therapy
chemotherapy regimen
  • 0 views
  • 05 Aug, 2020
Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

In Keynote181 study, for patients with metastatic esophageal squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved overall survival compared with chemotherapy. However, the efficacy and safety of immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced esophageal cancer still need a lot of clinical studies to further confirm.

  • 0 views
  • 05 Aug, 2020
Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

Strong and constant overexpression of PDL1 and NK cells has been found in all subtypes and settings of GTN tumors from French reference gestational trophoblastic center. Complete and durable responses to pembrolizumab were reported in 3 patients with multi-chemoresistant GTN in United Kingdom. Three cases of hCG normalization with avelumab …

  • 0 views
  • 05 Aug, 2020